Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Two Sigma Investments LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 226.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,664 shares of the company's stock after buying an additional 23,342 shares during the period. Two Sigma Investments LP owned about 0.08% of Keros Therapeutics worth $533,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of KROS. Barclays PLC lifted its stake in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after acquiring an additional 35,022 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after purchasing an additional 1,100 shares during the period. Y Intercept Hong Kong Ltd grew its position in Keros Therapeutics by 1,910.2% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 74,255 shares of the company's stock valued at $1,175,000 after purchasing an additional 70,561 shares in the last quarter. Bank of New York Mellon Corp grew its position in Keros Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock valued at $1,549,000 after purchasing an additional 2,462 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Keros Therapeutics by 7.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock valued at $4,427,000 after buying an additional 19,562 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Wedbush reissued a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the company from $32.00 to $18.00 in a report on Tuesday. Truist Financial decreased their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Finally, Wells Fargo & Company cut their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $30.56.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.60% of the stock is currently owned by insiders.

Keros Therapeutics Price Performance

Shares of KROS stock traded down $0.15 during trading hours on Thursday, hitting $13.64. 489,193 shares of the company's stock were exchanged, compared to its average volume of 860,896. The stock's 50-day moving average is $13.66 and its 200-day moving average is $17.41. The stock has a market cap of $553.99 million, a price-to-earnings ratio of -2.62 and a beta of 1.31. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same quarter last year, the business earned ($1.21) earnings per share. Equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.